CSTL

+ Watchlist + Portfolio

Castle Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $32.32
52-Week Range: $17.72 – $44.28
Market Cap: $1.01B
P/E (TTM): —
EPS (TTM): -0.64
Dividend Yield: —

Advanced Metrics

Price/Book: 2.14
PEG Ratio: —
Return on Equity: -4.20%
Return on Assets: -1.36%
Gross Margin: 77.26%
Operating Margin: -2.96%
Profit Margin: -5.43%
Current Ratio: 6.04
Debt/Equity: 0.08
Total Debt: $36.65M
Free Cash Flow: $-7.26M
Revenue Growth: 20.10%
Earnings Growth: —
Enterprise Value: $757.21M

CSTL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$137.04M	$219.79M	$332.07M	$344.23M
Cost of Revenue	$32.01M	$44.98M	$60.20M	$71.03M
Gross Profit	$105.03M	$174.81M	$271.86M	$273.20M
Research & Development	$44.90M	$53.62M	$52.04M	$51.85M
Selling, General & Admin	$143.00M	$180.15M	$200.05M	$229.32M
Operating Expenses	$196.17M	$242.78M	$263.19M	$316.01M
Operating Income	-$91.14M	-$67.98M	$8.67M	-$42.81M
EBITDA	-$58.34M	-$45.02M	$38.14M	$11.34M
Pretax Income	-$68.90M	-$57.37M	$21.56M	-$29.51M
Income Tax	-$1.77M	$101.00K	$3.32M	-$5.36M
Net Income	-$67.14M	-$57.47M	$18.25M	-$24.16M
Diluted EPS	-2.58	-2.14	0.62	-0.83
Diluted Shares	26.05M	26.80M	29.25M	28.99M

CSTL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$122.95M	$98.84M	$119.71M	$116.73M
Receivables	$23.48M	$38.30M	$51.22M	$43.38M
Inventory	$3.98M	$7.94M	$8.13M	$10.25M
Current Assets	$292.29M	$295.63M	$360.15M	$361.10M
Total Assets	$447.33M	$453.34M	$531.24M	$578.56M
Current Liabilities	$36.13M	$47.67M	$49.39M	$68.68M
Long-Term Debt	—	—	$9.74M	$9.64M
Total Debt	$13.40M	$15.34M	$26.34M	$36.91M
Total Liabilities	$48.18M	$62.07M	$75.40M	$107.68M
Retained Earnings	-$160.91M	-$218.37M	-$200.13M	-$224.28M
Shareholders' Equity	$399.15M	$391.27M	$455.83M	$470.87M
Working Capital	$256.16M	$247.97M	$310.76M	$292.42M

CSTL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$41.66M	-$5.63M	$64.87M	$64.35M
Capital Expenditure	-$5.63M	-$13.62M	-$28.33M	-$36.02M
Free Cash Flow	-$47.29M	-$19.25M	$36.54M	$28.33M
Depreciation & Amortisation	$10.54M	$12.33M	$16.00M	$40.77M
Stock-Based Compensation	$36.32M	$51.22M	$50.32M	$45.89M
Investing Cash Flow	-$166.54M	-$16.18M	-$50.14M	-$60.37M
Financing Cash Flow	$1.51M	-$2.30M	$6.14M	-$6.96M
Net Change in Cash	-$206.69M	-$24.11M	$20.87M	-$2.98M

CSTL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$87.99M	$86.19M	$83.04M	$87.01M	$83.68M
Cost of Revenue	$16.38M	$17.63M	$18.70M	$18.32M	$20.53M
Gross Profit	$71.61M	$68.56M	$64.34M	$68.69M	$63.15M
Research & Development	$12.59M	$12.79M	$12.96M	$13.52M	$14.43M
Selling, General & Admin	$58.62M	$58.06M	$55.91M	$56.73M	$64.90M
Operating Expenses	$99.53M	$72.81M	$71.14M	$72.52M	$81.55M
Operating Income	-$27.93M	-$4.25M	-$6.80M	-$3.83M	-$18.41M
EBITDA	$3.51M	$3.29M	$3.45M	$1.09M	-$10.35M
Pretax Income	-$26.27M	-$143.00K	-$386.00K	-$2.71M	-$14.41M
Income Tax	-$423.00K	-$4.67M	$115.00K	-$382.00K	$109.00K
Net Income	-$25.85M	$4.52M	-$501.00K	-$2.33M	-$14.52M
Diluted EPS	-0.90	0.15	-0.02	-0.08	-0.49
Diluted Shares	28.61M	29.55M	29.07M	29.33M	29.89M

CSTL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$89.69M	$82.23M	$85.56M	$116.73M	$63.76M
Receivables	$56.35M	$52.31M	$49.48M	$43.38M	$42.26M
Inventory	$6.85M	$8.37M	$8.65M	$10.25M	$10.46M
Current Assets	$349.39M	$348.67M	$357.57M	$361.10M	$328.90M
Total Assets	$501.71M	$544.73M	$562.79M	$578.56M	$547.80M
Current Liabilities	$37.27M	$50.89M	$55.31M	$68.68M	$48.76M
Long-Term Debt	$8.92M	$8.10M	$10.05M	$9.64M	$8.40M
Total Debt	$25.84M	$37.35M	$37.14M	$36.91M	$36.72M
Total Liabilities	$61.41M	$89.35M	$95.74M	$107.68M	$86.39M
Retained Earnings	-$225.97M	-$221.45M	-$221.95M	-$224.28M	-$238.81M
Shareholders' Equity	$440.31M	$455.38M	$467.05M	$470.87M	$461.42M
Working Capital	$312.11M	$297.78M	$302.26M	$292.42M	$280.14M

CSTL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$6.04M	$20.82M	$22.63M	$26.93M	-$22.13M
Capital Expenditure	-$4.74M	-$9.26M	-$14.83M	-$7.18M	-$12.46M
Free Cash Flow	-$10.78M	$11.56M	$7.80M	$19.75M	-$34.58M
Depreciation & Amortisation	$29.76M	$3.41M	$3.82M	$3.78M	$3.93M
Stock-Based Compensation	$11.18M	$11.21M	$12.10M	$11.41M	$9.78M
Investing Cash Flow	-$22.43M	-$28.38M	-$18.39M	$8.83M	-$25.80M
Financing Cash Flow	-$1.55M	$101.00K	-$919.00K	-$4.59M	-$5.03M
Net Change in Cash	-$30.02M	-$7.46M	$3.32M	$31.17M	-$52.97M

Market Snapshot

About

Castle Biosciences, Inc. is a commercial-stage diagnostics company focused on developing and commercializing molecular diagnostic tests for dermatologic cancers and other diseases. Headquartered in Friendswood, Texas, the company's flagship products include DecisionDx-Melanoma, a gene expression profile test that predicts metastatic risk in melanoma patients, and DecisionDx-SCC, which assesses squamous cell carcinoma risk. Castle Biosciences also offers tests for uveal melanoma and Barrett's esophagus. The company's proprietary technology helps physicians make more informed treatment decisions by providing personalized risk stratification for cancer patients.